JeanMarie
02-25-2017, 05:02 AM
Hi Everyone,
I haven't posted here in a long while. I found this today on a lymphoma site & it is relevant to us: TruximaTM, the first biosimilar mAb in oncology, granted EU marketing authorisation - News Press Release | PharmiWeb.com (http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=206802#.WLBkOn86xf6)
Its main advantage appears to be cost, which I guess is a good thing.
Keep fighting the good fight!
I haven't posted here in a long while. I found this today on a lymphoma site & it is relevant to us: TruximaTM, the first biosimilar mAb in oncology, granted EU marketing authorisation - News Press Release | PharmiWeb.com (http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=206802#.WLBkOn86xf6)
Its main advantage appears to be cost, which I guess is a good thing.
Keep fighting the good fight!